Address: Schipholweg 1, 2316 XB LEIDEN, The Netherlands
Tel: +31 (0)71 532 42 44
Web: http://worldwide.promega.com/country.aspx?returnUrl=/
We are a leader in providing innovative solutions and technical support to the life sciences industry. Promega Corporation’s 2,000 products enable scientists worldwide to advance their knowledge in life science research, particularly in genomics, proteomics, and cellular analysis. Our products are also used to support molecular diagnostics and human identification. Founded in 1978, Promega Corporation is headquartered in Madison, Wisconsin, USA, with branches in 14 countries and over 50 global distributors.
Promega’s first branch office was established in April 1984 in Leiden, The Netherlands.
Promega Corporation proudly supports the Molecular Diagnostics efforts of university, hospital, and commercial clinical labs with a long tradition of manufacturing reliability and excellence coupled with expert technical product support.
Promega produces reagents that are used as components or raw materials in the molecular biology applications that customers develop as part of their clinical research programs. These reagents are enzymes, signal detection systems, and purified biochemicals that, by themselves, generate no in vitro diagnostic test result whatsoever; when used in combination with other materials and systems provided by the end user, however, they serve as key components within the final in vitro diagnostic test that the customer has designed.
Promega is a truly global company with a vast international presence. What would you say is the strategic importance that the Benelux affiliate has assumed within Promega’s global network? Promega…
The EMA’s Peter Arlett looks back on two years of the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to improve the environment for clinical trials…
New methodology for the 2024 Access to Medicine Index promises a stronger attempt to quantify whether drugs, vaccines, and diagnostics are actually making it all the way to patients in…
Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to…
As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for…
In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the…
The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this…
The latest news from the Dutch pharma, biotech and healthcare industries, including the bullish comments of Argenx CEO Tim Van Hauwermeiren following the successful launch of its Vyvgart product; cancer…
The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use within the European Union, concluded a vote on Monday evening in Brussels following…
Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the…
Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015…
The Netherlands is clearly a fertile environment for its 2,200 life science and medtech companies. However, the Dutch ambition to be a frontrunner in new healthcare challenges also comprises an…
Sobi is a leading integrated biopharmaceutical company dedicated to developing innovative therapies and services to improve the lives of rare disease patients and their families. Karel Fol, the country manager…
See our Cookie Privacy Policy Here
